非恶性疾病的移植：国际细胞与基因治疗协会干细胞工程委员会的一份报告，关于替代供体、干细胞来源和移植物工程的作用。
Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering.
发表日期：2023 Jan 27
作者：
Orly R Klein, Carmem Bonfim, Allistair Abraham, Annalisa Ruggeri, Duncan Purtill, Sandra Cohen, Robert Wynn, Athena Russell, Akshay Sharma, Rachele Ciccocioppo, Susan Prockop, Jaap Jan Boelens, Alice Bertaina
来源：
CYTOTHERAPY
摘要：
造血干细胞移植（HSCT）对许多非恶性疾病具有治疗作用。随着HSCT和支持治疗技术的改进，这种挽救生命的治疗可能向更多患者提供。随着新的预备方案、扩大备选供体的可用性和移植物操作技术的发展，有很多选择最佳方案的选项。在此，作者回顾了进行HSCT的非恶性疾病患者的移植注意事项、移植目标、调理方案、供体选择和移植物操作策略。版权所有 © 2023国际细胞与基因治疗学会。 Elsevier Inc. 出版。保留所有权利。
Hematopoietic stem cell transplantation (HSCT) is curative for many non-malignant disorders. As HSCT and supportive care technologies improve, this life-saving treatment may be offered to more and more patients. With the development of new preparative regimens, expanded alternative donor availability, and graft manipulation techniques, there are many options when choosing the best regimen for patients. Herein the authors review transplant considerations, transplant goals, conditioning regimens, donor choice, and graft manipulation strategies for patients with non-malignant disorders undergoing HSCT.Copyright © 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.